Open AccessCardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors?
Author(s) -
Salvatrice Mancuso,
Marco Santoro,
Vincenzo Accurso,
Giuseppe Agliastro,
Simona Raso,
F. Di Piazza,
Alessandro Perez,
Marco Bono,
Antonio Russo,
Sergio Siragusa
Publication year - 2020
Publication title -
oncology research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.553
H-Index - 48
eISSN - 2296-5262
pISSN - 2296-5270
DOI - 10.1159/000509376
Subject(s) - medicine , polycythemia vera , population , risk factor , thrombosis , gastroenterology , environmental health
Cardiovascular risk factors are not considered in the current scores for evaluation of the thrombotic risk in myeloproliferative neoplasms, and in polycythemia vera (PV) in particular. Cytoreduction is currently not indicated in low-risk patients with PV, despite the absence or presence of cardiovascular risk factors. Our purpose is to highlight how cardiovascular risk factors in patients with PV increase the thrombotic risk both in low- and high-risk patients.